D7632C00001 Phase 3 Randomized Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig or Rilvegostomig Monotherapy vs Pembrolizumab Monotherapy for the 1st line treatment of Locally advanced or metastatic NonSquamous NSCLC with High PDL1 Expression and without actionable mutations

  • Phase III
  • Trial Category: Lung

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*